Global Botulinum Toxin Market
Global Botulinum Toxin Market

Botulinum Toxin Comprehensive Study by Type (Botulinum Toxin Type A, Botulinum Toxin Type B, Others), Application (Cosmetic Applications, Therapeutic Applications), End User (Hospitals, Ambulatory Care, Others) Players and Region - Global Market Outlook to 2024

Botulinum Toxin Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 223 Pages 185 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Botulinum Toxin Market Overview:
Botulinum toxin (BTX), a neurotoxic protein and muscle-relaxing medication that’s made from bacteria called Clostridium botulinum. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction and thus causes flaccid paralysis. Growing healthcare infrastructure in the developing economies and research and development in the healthcare industry expected to drive the demand for Botulinum toxin market in the upcoming years. Some of the key players profiled in the study are Allergan Plc. (Ireland), Nestlé Skin Health (Galderma) (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), Daewoong Pharmaceutical (South Korea), Ipsen Pharma (France), Medytox Inc. (South Korea), US WorldMeds LLC (United States), Revance Therapeutics Inc. (United States) and Metabiologics, Inc. (United States).

On the basis of geography, the market of Botulinum Toxin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the Botulinum Toxin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Surging Prevalence of Cervical Dystonia, Spasticity, Glabellar Lines and Crow’s Foot and Increase in the Use of Botulinum Toxin Type A
  • Rapid Adoption of Minimally Invasive Treatment Globally

Market Trend
  • Introduction of New and Improvised in Type B Products by Major Market Players

Restraints
  • High Cost of Botulinum Toxin

Opportunities
  • Increasing Cases of Migraine and Surge in the Demand for Non-Surgical Therapeutic Procedure
  • Rising Healthcare Expenditure in Developing Nations

Challenges
  • Stringent Government Regulations Regarding Drugs Approval
  • Intense Competition among Key Market Players




Target Audience:
Botulinum Toxin Manufacturers, Raw Material Suppliers, Product Suppliers/Distributors, End Users and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Botulinum Toxin market on the basis of product [Botulinum Toxin Type A, Botulinum Toxin Type B and Others] , application [Cosmetic Applications and Therapeutic Applications], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Botulinum Toxin market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Botulinum Toxin industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Botulinum Toxin market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Botulinum Toxin Type A
  • Botulinum Toxin Type B
  • Others
By Application
  • Cosmetic Applications
  • Therapeutic Applications
By End User
  • Hospitals
  • Ambulatory Care
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surging Prevalence of Cervical Dystonia, Spasticity, Glabellar Lines and Crow’s Foot and Increase in the Use of Botulinum Toxin Type A
      • 3.2.2. Rapid Adoption of Minimally Invasive Treatment Globally
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations Regarding Drugs Approval
      • 3.3.2. Intense Competition among Key Market Players
    • 3.4. Market Trends
      • 3.4.1. Introduction of New and Improvised in Type B Products by Major Market Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Botulinum Toxin, by Type, Application, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Botulinum Toxin (Value)
      • 5.2.1. Global Botulinum Toxin by: Type (Value)
        • 5.2.1.1. Botulinum Toxin Type A
        • 5.2.1.2. Botulinum Toxin Type B
        • 5.2.1.3. Others
      • 5.2.2. Global Botulinum Toxin by: Application (Value)
        • 5.2.2.1. Cosmetic Applications
        • 5.2.2.2. Therapeutic Applications
      • 5.2.3. Global Botulinum Toxin by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Care
        • 5.2.3.3. Others
      • 5.2.4. Global Botulinum Toxin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Botulinum Toxin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Plc. (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Nestlé Skin Health (Galderma) (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merz Pharma GmbH & Co. KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Daewoong Pharmaceutical (South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ipsen Pharma (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Medytox Inc. (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. US WorldMeds LLC (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Revance Therapeutics Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Metabiologics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Botulinum Toxin Sale, by Type, Application, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Botulinum Toxin (Value)
      • 7.2.1. Global Botulinum Toxin by: Type (Value)
        • 7.2.1.1. Botulinum Toxin Type A
        • 7.2.1.2. Botulinum Toxin Type B
        • 7.2.1.3. Others
      • 7.2.2. Global Botulinum Toxin by: Application (Value)
        • 7.2.2.1. Cosmetic Applications
        • 7.2.2.2. Therapeutic Applications
      • 7.2.3. Global Botulinum Toxin by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Care
        • 7.2.3.3. Others
      • 7.2.4. Global Botulinum Toxin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Botulinum Toxin: by Type(USD Million)
  • Table 2. Botulinum Toxin Botulinum Toxin Type A , by Region USD Million (2013-2018)
  • Table 3. Botulinum Toxin Botulinum Toxin Type B , by Region USD Million (2013-2018)
  • Table 4. Botulinum Toxin Others , by Region USD Million (2013-2018)
  • Table 5. Botulinum Toxin: by Application(USD Million)
  • Table 6. Botulinum Toxin Cosmetic Applications , by Region USD Million (2013-2018)
  • Table 7. Botulinum Toxin Therapeutic Applications , by Region USD Million (2013-2018)
  • Table 8. Botulinum Toxin: by End User(USD Million)
  • Table 9. Botulinum Toxin Hospitals , by Region USD Million (2013-2018)
  • Table 10. Botulinum Toxin Ambulatory Care , by Region USD Million (2013-2018)
  • Table 11. Botulinum Toxin Others , by Region USD Million (2013-2018)
  • Table 12. South America Botulinum Toxin, by Country USD Million (2013-2018)
  • Table 13. South America Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 14. South America Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 15. South America Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 16. Brazil Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 17. Brazil Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 18. Brazil Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 19. Argentina Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 20. Argentina Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 21. Argentina Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 22. Rest of South America Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 23. Rest of South America Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 25. Asia Pacific Botulinum Toxin, by Country USD Million (2013-2018)
  • Table 26. Asia Pacific Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 27. Asia Pacific Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 29. China Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 30. China Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 31. China Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 32. Japan Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 33. Japan Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 34. Japan Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 35. India Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 36. India Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 37. India Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 38. South Korea Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 39. South Korea Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 40. South Korea Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 41. Taiwan Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 42. Taiwan Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 43. Taiwan Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 44. Australia Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 45. Australia Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 46. Australia Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 50. Europe Botulinum Toxin, by Country USD Million (2013-2018)
  • Table 51. Europe Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 52. Europe Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 53. Europe Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 54. Germany Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 55. Germany Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 56. Germany Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 57. France Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 58. France Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 59. France Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 60. Italy Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 61. Italy Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 62. Italy Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 63. United Kingdom Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 64. United Kingdom Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 66. Netherlands Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 67. Netherlands Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 68. Netherlands Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 69. Rest of Europe Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 70. Rest of Europe Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 71. Rest of Europe Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 72. MEA Botulinum Toxin, by Country USD Million (2013-2018)
  • Table 73. MEA Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 74. MEA Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 75. MEA Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 76. Middle East Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 77. Middle East Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 78. Middle East Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 79. Africa Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 80. Africa Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 81. Africa Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 82. North America Botulinum Toxin, by Country USD Million (2013-2018)
  • Table 83. North America Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 84. North America Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 85. North America Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 86. United States Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 87. United States Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 88. United States Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 89. Canada Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 90. Canada Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 91. Canada Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 92. Mexico Botulinum Toxin, by Type USD Million (2013-2018)
  • Table 93. Mexico Botulinum Toxin, by Application USD Million (2013-2018)
  • Table 94. Mexico Botulinum Toxin, by End User USD Million (2013-2018)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Botulinum Toxin: by Type(USD Million)
  • Table 105. Botulinum Toxin Botulinum Toxin Type A , by Region USD Million (2019-2024)
  • Table 106. Botulinum Toxin Botulinum Toxin Type B , by Region USD Million (2019-2024)
  • Table 107. Botulinum Toxin Others , by Region USD Million (2019-2024)
  • Table 108. Botulinum Toxin: by Application(USD Million)
  • Table 109. Botulinum Toxin Cosmetic Applications , by Region USD Million (2019-2024)
  • Table 110. Botulinum Toxin Therapeutic Applications , by Region USD Million (2019-2024)
  • Table 111. Botulinum Toxin: by End User(USD Million)
  • Table 112. Botulinum Toxin Hospitals , by Region USD Million (2019-2024)
  • Table 113. Botulinum Toxin Ambulatory Care , by Region USD Million (2019-2024)
  • Table 114. Botulinum Toxin Others , by Region USD Million (2019-2024)
  • Table 115. South America Botulinum Toxin, by Country USD Million (2019-2024)
  • Table 116. South America Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 117. South America Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 118. South America Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 119. Brazil Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 120. Brazil Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 121. Brazil Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 122. Argentina Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 123. Argentina Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 124. Argentina Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 125. Rest of South America Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 126. Rest of South America Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 127. Rest of South America Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 128. Asia Pacific Botulinum Toxin, by Country USD Million (2019-2024)
  • Table 129. Asia Pacific Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 130. Asia Pacific Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 131. Asia Pacific Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 132. China Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 133. China Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 134. China Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 135. Japan Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 136. Japan Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 137. Japan Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 138. India Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 139. India Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 140. India Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 141. South Korea Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 142. South Korea Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 143. South Korea Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 144. Taiwan Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 145. Taiwan Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 146. Taiwan Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 147. Australia Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 148. Australia Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 149. Australia Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 150. Rest of Asia-Pacific Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 151. Rest of Asia-Pacific Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 152. Rest of Asia-Pacific Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 153. Europe Botulinum Toxin, by Country USD Million (2019-2024)
  • Table 154. Europe Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 155. Europe Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 156. Europe Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 157. Germany Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 158. Germany Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 159. Germany Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 160. France Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 161. France Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 162. France Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 163. Italy Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 164. Italy Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 165. Italy Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 166. United Kingdom Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 167. United Kingdom Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 168. United Kingdom Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 169. Netherlands Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 170. Netherlands Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 171. Netherlands Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 172. Rest of Europe Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 173. Rest of Europe Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 174. Rest of Europe Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 175. MEA Botulinum Toxin, by Country USD Million (2019-2024)
  • Table 176. MEA Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 177. MEA Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 178. MEA Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 179. Middle East Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 180. Middle East Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 181. Middle East Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 182. Africa Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 183. Africa Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 184. Africa Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 185. North America Botulinum Toxin, by Country USD Million (2019-2024)
  • Table 186. North America Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 187. North America Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 188. North America Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 189. United States Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 190. United States Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 191. United States Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 192. Canada Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 193. Canada Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 194. Canada Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 195. Mexico Botulinum Toxin, by Type USD Million (2019-2024)
  • Table 196. Mexico Botulinum Toxin, by Application USD Million (2019-2024)
  • Table 197. Mexico Botulinum Toxin, by End User USD Million (2019-2024)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Botulinum Toxin: by Type USD Million (2013-2018)
  • Figure 5. Global Botulinum Toxin: by Application USD Million (2013-2018)
  • Figure 6. Global Botulinum Toxin: by End User USD Million (2013-2018)
  • Figure 7. South America Botulinum Toxin Share (%), by Country
  • Figure 8. Asia Pacific Botulinum Toxin Share (%), by Country
  • Figure 9. Europe Botulinum Toxin Share (%), by Country
  • Figure 10. MEA Botulinum Toxin Share (%), by Country
  • Figure 11. North America Botulinum Toxin Share (%), by Country
  • Figure 12. Global Botulinum Toxin share by Players 2018 (%)
  • Figure 13. Global Botulinum Toxin share by Players (Top 3) 2018(%)
  • Figure 14. Global Botulinum Toxin share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Allergan Plc. (Ireland) Revenue: by Geography 2018
  • Figure 18. Nestlé Skin Health (Galderma) (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Nestlé Skin Health (Galderma) (Switzerland) Revenue: by Geography 2018
  • Figure 20. Merz Pharma GmbH & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Merz Pharma GmbH & Co. KGaA (Germany) Revenue: by Geography 2018
  • Figure 22. Daewoong Pharmaceutical (South Korea) Revenue, Net Income and Gross profit
  • Figure 23. Daewoong Pharmaceutical (South Korea) Revenue: by Geography 2018
  • Figure 24. Ipsen Pharma (France) Revenue, Net Income and Gross profit
  • Figure 25. Ipsen Pharma (France) Revenue: by Geography 2018
  • Figure 26. Medytox Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 27. Medytox Inc. (South Korea) Revenue: by Geography 2018
  • Figure 28. US WorldMeds LLC (United States) Revenue, Net Income and Gross profit
  • Figure 29. US WorldMeds LLC (United States) Revenue: by Geography 2018
  • Figure 30. Revance Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Revance Therapeutics Inc. (United States) Revenue: by Geography 2018
  • Figure 32. Metabiologics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Metabiologics, Inc. (United States) Revenue: by Geography 2018
  • Figure 34. Global Botulinum Toxin: by Type USD Million (2019-2024)
  • Figure 35. Global Botulinum Toxin: by Application USD Million (2019-2024)
  • Figure 36. Global Botulinum Toxin: by End User USD Million (2019-2024)
  • Figure 37. South America Botulinum Toxin Share (%), by Country
  • Figure 38. Asia Pacific Botulinum Toxin Share (%), by Country
  • Figure 39. Europe Botulinum Toxin Share (%), by Country
  • Figure 40. MEA Botulinum Toxin Share (%), by Country
  • Figure 41. North America Botulinum Toxin Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Allergan Plc. (Ireland)
  • Nestlé Skin Health (Galderma) (Switzerland)
  • Merz Pharma GmbH & Co. KGaA (Germany)
  • Daewoong Pharmaceutical (South Korea)
  • Ipsen Pharma (France)
  • Medytox Inc. (South Korea)
  • US WorldMeds LLC (United States)
  • Revance Therapeutics Inc. (United States)
  • Metabiologics, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation